ekaterina dadachova

April 26, 2010 — Tiny, melanin-covered nanoparticles may protect bone marrow from the harmful effects of radiation therapy, according to scientists at Albert Einstein College of Medicine of Yeshiva University who successfully tested the strategy in mouse models. The research is published in the April 26, 2010 issue of the International Journal of Radiation Oncology, Biology and Physics.

Ekaterina Dadachova, Ph.D., the Sylvia & Robert S. Olnick Faculty Scholar in Cancer Research, discusses the technology she invented with Arturo Casadevall, M.D., Ph.D., and Joshua Nosanchuk, M.D. The technology, radioimmunotherapy of metastatic melanoma with radiolabeled melanin-binding antibodies, was invented at Einstein and is now in clinical trials sponsored by Pain Therapeutics. (September 24, 2009)

Panelists discuss an Einstein innovation moving from "bench to bedside." Einstein-invented technology intended to treat metastatic melanoma is in clinical trials by Pain Therapeutics, Inc. Panelists include: Ekaterina Dadachova, Ph.D., the Sylvia & Robert S. Olnick Faculty Scholar in Cancer Research; John Harb, director of the office of biotechnology; and Remi Barbier,CEO of Pain Therapeutics, Inc. (September 24, 2009)